AFFiRiS AG

AFFiRiS develops first-in-class antigen specific vaccines for the prevention and treatment of chronic illnesses. Our proprietary AFFITOME®-Technology delivers peptides that are optimized to mimic a target specific epitope, thereby inducing an antibody response that is cross-reactive to the original target. Our clinical stage projects focus on Atherosclerosis prevention targeting PCSK9 and Parkinson’s disease targeting α synuclein.

  • Mitarbeiterzahl

    77
  • Ausrichtungen
    • Therapie-Entwickler
  • Gegründet

    2003
  • Aktualisiert am

    30.05.2018